Organoids are made to model human organs and are promising for research and therapy, but there are limitations to their ...

Tumour hypoxia has been pursued as a cancer drug target for over 30 years, most notably using bioreductive (hypoxia-activated) prodrugs that target antineoplastic agents to low-oxygen tumour ...